Certificate under Regulation 74(5) of SEBI (Depository and Participants) Regulations, 2018 for the 4th Quarter and Annual year ended 31st MArch, 2026.

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+8.0%1-day move

₹0.25

prior close

₹0.25

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+4.0+4.0+4.0+4.0+8.0+16.0+24.0+36.0+36.0+32.0+16.0+20.0+8.0+8.0

Up moveDown movePending

AI summary

Welcure Drugs & Pharmaceuticals Ltd has submitted a routine regulatory compliance certificate confirming that no physical share certificates were received for dematerialization during Q4 and the full financial year ended March 31, 2026. The confirmation was issued by Skyline Financial Services Pvt Ltd, the company's Registrar and Transfer Agent. This filing is a standard requirement under SEBI regulations to ensure transparency in the dematerialization process. The company (Scrip Code: 524661, ISIN: INE331C01025) is up to date with its regulatory obligations. The certificate was digitally signed by Managing Director & CFO Chintan Didawala Ganpat on April 3, 2026.

Likely market impact

This is a routine compliance filing with no direct impact on the stock price or shareholder value. It simply confirms that the company's share dematerialization process is running normally without any outstanding physical certificates to process.